Compare FSTR & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSTR | VYGR |
|---|---|---|
| Founded | 1902 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 442.3M | 216.3M |
| IPO Year | 1995 | 2015 |
| Metric | FSTR | VYGR |
|---|---|---|
| Price | $37.77 | $3.14 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $32.00 | $16.50 |
| AVG Volume (30 Days) | 31.0K | ★ 376.4K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $540,009,000.00 | $10,135,000.00 |
| Revenue This Year | $5.12 | $34.04 |
| Revenue Next Year | $2.78 | $7.92 |
| P/E Ratio | $84.89 | ★ N/A |
| Revenue Growth | ★ 1.74 | N/A |
| 52 Week Low | $24.30 | $2.94 |
| 52 Week High | $45.81 | $5.55 |
| Indicator | FSTR | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 43.00 | 41.56 |
| Support Level | $36.53 | $2.95 |
| Resistance Level | $38.68 | $3.30 |
| Average True Range (ATR) | 0.94 | 0.13 |
| MACD | 0.13 | -0.03 |
| Stochastic Oscillator | 34.08 | 21.95 |
L.B. Foster Co is a technology solutions provider of products and services for the rail and infrastructure markets. The company has two reporting segments: Rail, Technologies, and Services (Rail); and Infrastructure Solutions (Infrastructure). Maximum revenue is generated from the Rail segment, which is comprised of several manufacturing and distribution businesses that provide products and services for freight and passenger railroads and industrial companies throughout the world. The Infrastructure segment offers engineered precast concrete solutions, as well as fabricated bridge, protective pipe coating, and pipe threading offerings across North America. Geographically, the company generates maximum revenue from the United States, followed by Canada, the UK, and other markets.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.